| http://www.w3.org/ns/prov#value | - In 1993, new regulations codified FDA's authority to require Phase IV studies for certain new drugs.[1] Under these regulations, when the FDA approves an application on the basis of a surrogate endpoint or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity, the agency can require Phase IV studies as a condition of approval.
|
